

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

Attachment 22  
August 25, 2026

【Therapeutic category】 625 Anti-virus agents

【Non-proprietary name】 Rilpivirine

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

| Current                                                                                                                                                                                                                                    |                                                                 |                                                         | Revision                                                                                                                                                                                                                                                                                              |                                                                 |                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------|
| 2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)                                                                                                                                                             |                                                                 |                                                         | 2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)                                                                                                                                                                                                                        |                                                                 |                                                         |
| Patients receiving rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin, fosphenytoin, apalutamide, enzalutamide, dexamethasone (systemic administration) (excluding single administration), and food containing St. John's Wort |                                                                 |                                                         | Patients receiving rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin, fosphenytoin, apalutamide, enzalutamide, <u>ivosidenib</u> , <u>encorafenib</u> , <u>mitotane</u> , dexamethasone (systemic administration) (excluding single administration), and food containing St. John's Wort |                                                                 |                                                         |
| 10. INTERACTIONS                                                                                                                                                                                                                           |                                                                 |                                                         | 10. INTERACTIONS                                                                                                                                                                                                                                                                                      |                                                                 |                                                         |
| 10.1 Contraindications for Co-administration (Do not co-administer with the following)                                                                                                                                                     |                                                                 |                                                         | 10.1 Contraindications for Co-administration (Do not co-administer with the following)                                                                                                                                                                                                                |                                                                 |                                                         |
| Drugs                                                                                                                                                                                                                                      | Signs, symptoms, and treatment                                  | Mechanism/risk factors                                  | Drugs                                                                                                                                                                                                                                                                                                 | Signs, symptoms, and treatment                                  | Mechanism/risk factors                                  |
| Apalutamide<br>Enzalutamide                                                                                                                                                                                                                | The blood concentration of this drug may decrease, leading to a | The CYP3A-inducing activity of these drugs promotes the | Apalutamide<br>Enzalutamide<br><u>Ivosidenib</u>                                                                                                                                                                                                                                                      | The blood concentration of this drug may decrease, leading to a | The CYP3A-inducing activity of these drugs promotes the |

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

|  |                                           |                          |  |                    |                             |                          |
|--|-------------------------------------------|--------------------------|--|--------------------|-----------------------------|--------------------------|
|  | reduction in the effects of<br>this drug. | metabolism of this drug. |  | <u>Encorafenib</u> | reduction in the effects of | metabolism of this drug. |
|  |                                           |                          |  | <u>Mitotane</u>    | this drug.                  |                          |
|  |                                           |                          |  |                    |                             |                          |

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*